Protecting kidneys from platinum chemotherapy damage
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a way to protect your kidneys while you receive platinum-based chemotherapy (cisplatin or carboplatin) for a solid tumor. It may help reduce the risk of kidney damage so you can complete your treatment more safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a solid tumor that your doctor plans to treat with cisplatin or carboplatin chemotherapy.
- You must be expected to live at least 4 months and be well enough to perform daily activities (ECOG score 0-2).
- You cannot have had a kidney removed or a kidney transplant.
- You cannot have poorly controlled diabetes (type 1, or type 2 with high blood sugar levels).
- Your kidney function must be relatively good (eGFR above 20) and you cannot have certain other kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a supplement called alpha-lipoic acid can help protect your kidneys from damage caused by cisplatin, a common chemotherapy drug. If it works, it could reduce side effects and help you tolerate your cancer treatment better.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This study tests whether dapagliflozin can preserve the structure and function of a kidney transplant. You may be asked to take dapagliflozin on top of usual transplant medicines to see if it helps the new kidney work better over time.
This study tests whether a common diabetes medication (SGLT2 inhibitor) can help people with autosomal dominant polycystic kidney disease (ADPKD) maintain kidney function longer. If you have fast-growing kidney cysts and are between 18 and 60 years old, this trial may be an option.
This trial tests whether empagliflozin, a medication originally for diabetes, can help protect the remaining kidney function in people who have just started peritoneal dialysis. If you started dialysis within the last 3 months and still make some urine, this study may be a good fit.
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.